MedTrace Logo

Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma

NCT02275416 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-12-16

No results posted yet for this study

Summary

This study, with 20 patients participating, will examine the safety and tolerability for the ipilimumab/UV1 combination in patients with unresectable or metastatic malignant melanoma.

Conditions

  • Malignant Melanoma

Interventions

DRUG

Ipilimumab

BIOLOGICAL

UV1 vaccine

BIOLOGICAL

GM-CSF

Sponsors & Collaborators

  • Oslo University Hospital

    collaborator OTHER

  • Ultimovacs ASA

    lead INDUSTRY

Principal Investigators

  • Tormod Guren, MD PhD · Oslo University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-02
Primary Completion
2016-10-06
Completion
2020-11-03

Countries

  • Norway

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02275416 on ClinicalTrials.gov